Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	19611
Country	Italy

Received	2015-05-14 09:02
Peer-Review Started	2015-05-15 15:45
To Make the First Decision	2015-09-08 10:32
Return for Revision	2015-09-16 16:17
Revised
Second Decision	2016-05-30 12:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-06-16 11:36
Articles in Press	2016-06-16 11:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-20 09:00
Publish the Manuscript Online	2016-08-01 11:49

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?
Manuscript Source	Invited Manuscript
All Author List	Gianluca Andrisani, Alessandro Armuzzi, Manuela Marzo, Carla Felice, Daniela Pugliese, Alfredo Papa and Luisa Guidi
Funding Agency and Grant Number
Corresponding Author	Luisa Guidi, MD, PhD, IBD Unit, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, via Moscati 31, 00168 Rome, Italy. guidi@rm.unicatt.it
Key Words	Inflammatory bowel disease; Opportunistic infections; Immunomodulators; Corticosteroids; Anti-tumor necrosis factor agents
Core Tip	The increasing use of biologics as a mainstay of therapy in inflammatory bowel disease (IBD) is associated with an increased risk for a variety of infections, many of which are preventable by prior screening and vacci?nation. While immunocompetent IBD patients can be vaccinated using standard vaccination schedule, special guidelines need to be followed for IBD patients getting immunosuppressive therapy (IST). This article provides a review of the issues surrounding immunizations in the IBD patient and a practical guide for clinicians regarding the appropriate screening for infections and vaccinations to administer both before and during IST.
Publish Date	2016-08-01 11:49
Citation	Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396
URL	http://www.wjgnet.com/2150-5349/full/v7/i3/387.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v7.i3.387

Full Article (PDF)	WJGPT-7-387.pdf
Full Article (Word)	WJGPT-7-387.doc
Manuscript File	19611-Review.docx
Answering Reviewers	19611-Answering reviewers.pdf
Audio Core Tip	19611-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19611-Conflict-of-interest statement.pdf
Copyright License Agreement	19611-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	19611-Language certificate.pdf
Peer-review Report	19611-Peer-review(s).pdf
Scientific Misconduct Check	19611-Scientific misconduct check.pdf
Scientific Editor Work List	19611-Scientific editor work list.pdf